Navigation Links
Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
Date:3/19/2013

ion index of 43% compared to the standard Framingham method.

"As a cardiologist, I am excited about the prospect of this test. I understand its value to my patients and practice and I was happy to speak to my colleagues about its usefulness in the clinic," stated Dr. Simonini.

Aviir CEO Douglas Harrington , MD, said Aviir anticipates that the MIRISK VP test will become an important and widely used tool for physicians who want to provide their patients with a clearer picture of their individual heart health by providing critical information to high risk patients who may be incorrectly identified as intermediate risk by standard diagnostic methods.

About the MIRISK VP™ Assessment

The Aviir MIRISK VP test was developed out of research performed at the Stanford University School of Medicine. Researchers identified seven key proteins associated with the biological processes underlying formation and rupture of vulnerable plaque, which is the number one cause of a heart attack. MIRISK VP was shown to effectively measure these proteins in a patient's blood up to 5 years prior to an ensuing heart attack or unstable angina. Aviir's scientists developed sensitive multiplexed assays as well as a proprietary algorithm to detect those key proteins in an individual's blood and combines them with additional clinical risk factors to generate a more accurate 5-year risk score assessment for coronary heart disease (CHD). In an independent study, the MIRISK VP algorithm was shown to reclassify intermediate risk individuals as actually belonging either in a high or low risk group, significantly improving risk stratification (net reclassification index of 43%). By identifying patients who are actually at high risk, MIRISK VP assists physicians in developing effective treatment plans and implementing preventative measures to reduce the risk of a heart attack when they can be most beneficial. When used in conjunction with addi
'/>"/>

SOURCE Aviir Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
3. Dr. James Douglas Adds Human Growth Hormone (HGH) Therapy to IVF Protocols for Poor Responding Patients
4. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
5. inVentiv Health Selected to Provide Sales Operations Support for Santarus
6. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
7. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
8. Sequenom Named to NASDAQ Global Select Market
9. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
10. First Choice Rehabilitation Specialists Joins Select Medical
11. Netsmart Selects Overland Park, Kansas, for New Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)...  NeuroSigma, Inc., a Los Angeles ... today announced that it has filed a registration statement ... Commission relating to a proposed initial public offering of ... offered and the price range for the proposed offering ... will act as the book-running manager for the proposed ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... young scientists have received postdoctoral fellowships from the National ... they conduct research with the eventual aim of protecting ... mentorship from a faculty member at their home institution, ... research teams. This allows them to interact with some ...
... from a pivotal, large-scale Phase III trial, published online ... , show that the RTS,S malaria vaccine candidate can ... immunization with a control vaccine, infants (aged 6-12 weeks ... episodes of both clinical and severe malaria and had ...
... Nearly 3,000 insect scientists are expected to attend Entomology 2012, ... this November in Knoxville, TN. Members of the media who ... press pass. WHEN: November 11-14, 2012 ... WHAT: Entomology 2012 is the 60th Annual ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4
... Edited by N.C. Price (1996) ... information on protein chemistry and ... of proteins. Data on the ... crystalization, size determination, amino acid ...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: